



2026 New Developments in PCNSL Treatment

A Primary Central Nervous System Lymphoma Patient Disease Education Webinar



**March 27, 2026
11AM - 1PM PT**

This online event, produced and moderated by the End Brain Cancer Initiative (EBCI) will allow members of the Primary Central Nervous System Lymphoma (PCNSL) community to hear directly from top experts in the neuro-oncology field about new research, clinical trials, specialists, treatments, diagnostics, support, and more.

REGISTER NOW

Register today to receive the Zoom information to join this online event.

This Patient Disease Education Webinar Supported By

deciphera
a member of
ONO PHARMA

Dana-Farber
Cancer Institute



HARVARD
MEDICAL SCHOOL

BELAY
DIAGNOSTICS



WHIM
social

Memorial Sloan Kettering
Cancer Center

CURIS

SPEAKERS



Dellann Elliott Mydland
End Brain Cancer Initiative
President & CEO



Dr. Lakshmi Nayak, M.D.
Dana-Farber Cancer Institute
Neuro-oncologist & Director of the
Center for CNS Lymphoma



Cameron L. Lilly, PhD
Belay Diagnostics
Medical Science Liaison



Christian Grommes, MD
Memorial Sloan Kettering Cancer Center
Neuro-Oncologist & Early Drug
Development Specialist



Dr. Ahmed Hamdy
Curis
Chief Medical Officer



Shreya Prakash
End Brain Cancer Initiative
Patient & Resource Navigator/
Clinical Trial Coordinator

Chris Elliott Fund®
endobrain cancer
Fueling Research & Clinical Trial Enrollment

**New
Developments
in PCNSL
Treatments**



2026 New Developments in PCNSL Treatment

A Primary Central Nervous System Lymphoma Patient Disease Education Webinar

AGENDA

10:45 AM

Zoom Meeting Opens

The program will start right at 11 AM PT

11 AM

Welcome & Introduction

Dellann Elliott Mydland, EBCI President & CEO

11:10 AM

"PCNSL Study Results & New Clinical Trials" and Q&A
Dr. Lakshmi Nayak, M.D., Dana-Farber Cancer Institute Neuro-oncologist & Director of the Center for CNS Lymphoma

11:45 AM

"Diagnostic Testing for CNS Tumors" and Q&A
Cameron L. Lilly, PhD, Belay Diagnostics Medical Science Liaison

12:05 PM

"The EIFEL Trial for Refractory/Recurrent CNS Lymphoma" and Q&A
Christian Grommes, MD, Memorial Sloan Kettering Cancer Center Neuro-Oncologist & Early Drug Development Specialist

12:25 PM

"The TakeAim Lymphoma Clinical Trial" and Q&A
Dr. Ahmed Hamdy, Curis Chief Medical Officer

12:45 PM

"EBCI Patient/Caregiver and Clinical Trial Navigation Services" and Q&A
Shreya Prakash, EBCI Patient & Resource Navigator/Clinical Trial Coordinator

12:55 PM

Closing
Dellann Elliott Mydland, EBCI President & CEO



This Patient Disease Education Webinar Supported By



Memorial Sloan Kettering
Cancer Center

